[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586825":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":17,"collaborators":10,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":26,"acronym":10,"eligibilityCriteria":27,"healthyVolunteers":28,"sex":29,"minAge":30,"maxAge":31,"enrollmentInfo":32,"targetDuration":10,"studyType":35,"phases":10,"briefSummary":36,"conditions":37,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":10},{"fullName":5,"class":6},"Southeast University, China","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Xuebijing treatment group",null,"Based on the standard treatment group Xuebijing injection was added.",{"label":13,"type":10,"description":14,"interventionNames":10},"Standard treatment group","Patients with sepsis are given standard treatment according to international guidelines for the management of sepsis and septic shock",{"label":16,"type":10,"description":10,"interventionNames":10},"Healthy Volunteer Group",{"type":18,"investigatorFullName":19,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Songqiao Liu","Prof","100586825","novel-biomarkers-related-xuebijing-injection-improves-sepsis-100586825",false,"NCT06920420","Novel Biomarkers Related Xuebijing Injection Improves Sepsis","Xuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2\u002FBAX\u002FAIM2 Pathway","Inclusion Criteria:\n\n1. Meeting the Sepsis 3.0 diagnostic criteria;\n2. SOFA score ≥ 2 and \\\u003C 13;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years or \\>75 years;\n2. Pregnant or lactating women;\n3. Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;\n4. Current use of immunosuppressants or history of organ transplantation within the past 6 months;\n5. Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.",true,"ALL","18 Years","75 Years",{"count":33,"type":34},30,"ESTIMATED","OBSERVATIONAL","Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.",[38],"Sepsis","NOT_YET_RECRUITING","2025-04-01",{"date":42,"type":43},"2025-04-09","ACTUAL",{"date":45,"type":34},"2025-03-30",{"date":47,"type":34},"2028-12-31",{"name":5,"class":6}]